Skip to content

Cerus CERS Net Investment in Lease

Net Investment in Lease at other companies

Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
QuidelOrtho Corporation logo
QuidelOrtho CorporationQDEL
ADMA Biologics logo
ADMA BiologicsADMA
Paysign logo
PaysignPAYS

Other financials

Income statement

See full
Revenue$53.7M+24.1%
Operating income-$354.0K+94.0%
Net income-$1.6M+78.7%
EPS (diluted)-$0.01+75.0%

Balance sheet

See full
Cash & equivalents$27.9M+43.0%
Total debt$45.0M-43.3%
Total equity$67.6M+21.7%
Total assets$222.9M+7.8%

Cash flow

See full
Operating cash flow-$3.0M-261%
CapEx$233.0K+108%
Free cash flow-$3.3M-243%

Valuation

See full
Market cap$573.06M+124%
Enterprise value$590.17M+86.7%
P/S2.9×-1.0×

Profitability

See full
Gross margin64%
Operating margin-6.2%-2.1pp
Net margin-9.8%-2.8pp
FCF margin3.5%+1.9pp

Returns & leverage

See full
Return on equity-15.5%-5.6pp
Debt / equity0.7×-0.8×
Current ratio1.6×-0.7×

Where this comes from

Reported directly by Cerus in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Cerus’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cerus's net investment in lease.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cerus's net investment in lease?
Cerus (CERS) reported net investment in lease of $9.45M in Q1 2026.
How has Cerus's net investment in lease changed year-over-year?
Cerus's net investment in lease increased by 3.8% year-over-year, from $9.1M to $9.45M.
What is the long-term trend for Cerus's net investment in lease?
Over 5 years (2020 to 2025), Cerus's net investment in lease has grown at a -5.1% compound annual growth rate (CAGR), from $13.12M to $10.12M.